Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Geron Corporation
  6. Summary
    GERN   US3741631036

GERON CORPORATION

(GERN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
1.42(c) 1.45(c) 1.45(c) 1.46(c) 1.45(c) Last
1 844 341 813 828 980 044 1 284 013 1 062 396 Volume
+0.71% +2.11% 0.00% +0.69% -0.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,38 M - -
Net income 2021 -116 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,11x
Yield 2021 -
Sales 2022 0,30 M - -
Net income 2022 -131 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,77x
Yield 2022 -
Capitalization 465 M 465 M -
Capi. / Sales 2021 1 219x
Capi. / Sales 2022 1 550x
Nbr of Employees 54
Free-Float 99,8%
More Financials
Company
Geron Corporation is a late-stage clinical biopharmaceutical company, which is focused on the development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and... 
More about the company
Ratings of Geron Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GERON CORPORATION
10/21GERON : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
10/18GERON : Completes Patient Enrollment in Phase 3 Trial of Imetelstat
MT
10/18GERON : Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Low..
BU
10/18Geron Announces Completion of Patient Enrollment in Imerge Phase 3 Clinical Trial in Lo..
CI
10/15GERON : to Host a Virtual Investor Event in November
BU
10/12AFTER HOURS WATCH LIST SCORECARD : Qtrx, gern, rlay
MT
10/11MT NEWSWIRES AFTER HOURS WATCH LIST : Qtrx, gern, rlay
MT
10/11GERON : Imetelstat Shows Survival Benefit in BLood Cancer Trial -- Stock Up 8% After-Hours
MT
10/11GERON : Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in A..
BU
10/11Geron Corporation Announces Publication of Analyses Comparing Real World Data to IMbark..
CI
09/30GERON : 2021 Cantor Global Healthcare Conference
PU
09/16GERON : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
09/14GERON : R.W. Baird Global Healthcare Conference
PU
09/13GERON : HC Wainwright Healthcare Conference
PU
09/01GERON : Announces September Investor Conference Presentation Webcasts
BU
More news
News in other languages on GERON CORPORATION
10/18Geron achève le recrutement de patients pour l'essai de phase 3 de l'Imetelstat
10/11L'Imetelstat de Geron présente un avantage en termes de survie lors d'un essai sur le c..
2014Wall Street ouvre étale après les ventes au détail
2014Les valeurs à suivre à Wall Street
2014Wall Street finit en baisse, inquiétudes sur l'Irak
More news
Chart GERON CORPORATION
Duration : Period :
Geron Corporation Technical Analysis Chart | GERN | US3741631036 | MarketScreener
Technical analysis trends GERON CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,45 $
Average target price 4,25 $
Spread / Average Target 193%
EPS Revisions
Managers and Directors
John A. Scarlett Chairman, President & Chief Executive Officer
Olivia K. Bloom Chief Financial Officer, Treasurer & Executive VP
Aleksandra Rizo Chief Medical Officer & Executive Vice President
Andrew J. Grethlein Chief Operating Officer & Executive Vice President
Karin Eastham Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GERON CORPORATION-8.81%465
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610